Progyny (NASDAQ:PGNY) Sets New 52-Week High – Still a Buy?

Progyny, Inc. (NASDAQ:PGNY)’s stock price hit a new 52-week high during mid-day trading on Monday . The company traded as high as $31.49 and last traded at $31.4770, with a volume of 98994 shares trading hands. The stock had previously closed at $30.65.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on PGNY shares. Citigroup restated an “outperform” rating on shares of Progyny in a research report on Monday, May 11th. Barclays increased their price objective on Progyny from $23.00 to $27.00 and gave the company an “overweight” rating in a research note on Friday, May 15th. Zacks Research upgraded shares of Progyny from a “hold” rating to a “strong-buy” rating in a report on Wednesday, July 8th. Weiss Ratings upgraded shares of Progyny from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday, June 26th. Finally, Wall Street Zen upgraded shares of Progyny from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 27th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $30.73.

Progyny Trading Up 3.6%

The stock has a market cap of $2.49 billion, a PE ratio of 41.25, a P/E/G ratio of 2.43 and a beta of 1.01. The business has a fifty day simple moving average of $25.85 and a two-hundred day simple moving average of $22.66.

Progyny (NASDAQ:PGNY) last issued its quarterly earnings results on Thursday, May 7th. The company reported $0.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.26 by $0.24. Progyny had a net margin of 5.23% and a return on equity of 13.34%. The company had revenue of $328.50 million during the quarter, compared to analysts’ expectations of $326.46 million. During the same period last year, the company posted $0.17 EPS. Progyny’s revenue was down 26.4% on a year-over-year basis. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. On average, research analysts predict that Progyny, Inc. will post 1.19 earnings per share for the current year.

Progyny declared that its Board of Directors has authorized a share repurchase program on Tuesday, May 26th that permits the company to repurchase $200.00 million in shares. This repurchase authorization permits the company to repurchase up to 10.3% of its stock through open market purchases. Stock repurchase programs are often an indication that the company’s leadership believes its shares are undervalued.

Insiders Place Their Bets

In other news, CFO Mark S. Livingston sold 8,275 shares of the business’s stock in a transaction on Wednesday, May 20th. The stock was sold at an average price of $25.50, for a total value of $211,012.50. Following the completion of the transaction, the chief financial officer owned 79,063 shares in the company, valued at $2,016,106.50. The trade was a 9.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Melissa B. Cummings sold 9,578 shares of the business’s stock in a transaction on Tuesday, May 19th. The stock was sold at an average price of $25.00, for a total value of $239,450.00. Following the completion of the transaction, the chief operating officer owned 73,371 shares of the company’s stock, valued at $1,834,275. This represents a 11.55% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 36,916 shares of company stock worth $939,875 in the last three months. Corporate insiders own 9.90% of the company’s stock.

Institutional Investors Weigh In On Progyny

Large investors have recently bought and sold shares of the business. Royal Bank of Canada lifted its stake in Progyny by 384.8% during the 1st quarter. Royal Bank of Canada now owns 13,027 shares of the company’s stock valued at $291,000 after acquiring an additional 10,340 shares during the period. Amundi boosted its holdings in shares of Progyny by 103.8% during the 1st quarter. Amundi now owns 11,419 shares of the company’s stock valued at $264,000 after acquiring an additional 5,817 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Progyny by 6.0% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 252,032 shares of the company’s stock worth $5,630,000 after acquiring an additional 14,297 shares during the period. Invesco Ltd. grew its stake in shares of Progyny by 37.4% in the second quarter. Invesco Ltd. now owns 379,189 shares of the company’s stock worth $8,342,000 after acquiring an additional 103,253 shares during the period. Finally, Walleye Capital LLC raised its holdings in shares of Progyny by 6.9% during the second quarter. Walleye Capital LLC now owns 12,080 shares of the company’s stock valued at $266,000 after purchasing an additional 780 shares during the last quarter. 94.93% of the stock is currently owned by institutional investors.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.